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most common drug-related adverse effects included neu-
tropenia, fatigue, leukopenia, nausea, alopecia, diarrhea, 
and decreased appetite. A trend toward a decrease in pHH3 
was observed, with increasing BI 811283 doses, indicating 
target engagement; there was no consistent trend regarding 
caspase-cleaved CK-18 levels. No objective response was 
observed although 19 patients in each schedule achieved 
clinical benefit (stable disease).
Conclusions BI 811283 demonstrated a generally man-
ageable safety profile and disease stabilization in some 
patients.
Trial registration EudraCT No: 2007-000191-17, Clinical-
Trials.gov Identifier: NCT00701324.
Keywords Aurora B kinase · BI 811283 · Phase I · Mitosis 
modulators · Solid tumors
Abstract 
Purpose This phase I study investigated the maximum 
tolerated dose (MTD), safety, pharmacokinetics, pharma-
codynamics, and antitumor activity of the Aurora B kinase 
inhibitor BI 811283 in patients with advanced solid tumors.
Methods BI 811283 was administered via 24-h infusion on 
Days 1 and 15 of a 4-week cycle (schedule A) or Day 1 
of a 3-week cycle (schedule B) in a modified 3 + 3 dose-
escalation design. Pharmacodynamic assessments included 
immunohistochemistry for phosphorylated histone H3 
(pHH3) on skin biopsies to determine Aurora B kinase 
inhibition and plasma concentrations of caspase-cleaved 
CK-18 (apoptosis marker).
Results A total of 121 patients were treated. The MTDs of 
BI 811283 were 125 mg (schedule A) and 230 mg (sched-
ule B). Dose-limiting toxicities were primarily hemato-
logical (febrile neutropenia and grade 4 neutropenia); the 
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Background
The Aurora kinases belong to a family of three serine/thre-
onine protein kinases (A, B, and C) that have a prominent 
role in regulating cell division [1, 2]. Aurora B kinase is part 
of the chromosome passenger complex (CPC), a group of 
proteins identified by its change in cellular localization over 
the duration of the cell cycle [3, 4]. Aurora B kinase has an 
important role in regulating many aspects of mitotic cell 
division, such as chromosome bi-orientation and sister chro-
matid cohesion, where Aurora B kinase is associated with 
the centromeres [5, 6], and spindle disassembly and cytoki-
nesis following re-localization of the CPC to the midbody 
[7]. Furthermore, Aurora B kinase assists with chromosome 
condensation via phosphorylated histone H3 (pHH3) [8, 9].
There is considerable evidence linking Aurora B kinase to 
tumorigenesis. An increased expression of Aurora B kinase 
promotes chromosome instability and aneuploidy in vitro 
[10], and cells overexpressing Aurora B kinase have been 
shown to form aggressive tumors in nude mice [11]. In vivo, 
overexpression of Aurora B kinase is associated with several 
different tumor types when compared with matched normal 
tissue, such as brain, thyroid, breast, lung, colorectal, and 
prostate cancers, and is linked with characteristics including 
genetic instability, disease progression, and poor outcome 
in these patients [12–19]. In vitro, cells lacking Aurora B 
kinase cannot complete cytokinesis, become tetraploid and 
subsequently die [20]. This, together with the essential func-
tions of Aurora B kinase during cell replication and its ele-
vated expression in many cancer cell types, suggests that this 
mitotic enzyme is a valid target for therapeutic intervention.
There are multiple Aurora kinase inhibitors in preclinical 
studies or clinical trials. These agents are either pan-Aurora 
kinase inhibitors (targeting Aurora A, B, and occasionally 
C), or specific for either Aurora A or Aurora B [21].
BI 811283 is an adenosine triphosphate-competitive, 
reversible, and potent inhibitor of Aurora B kinase (half-
maximal inhibitory concentration [IC50], 9 nM) [22, 23]. 
In a preclinical, in vitro study, BI 811283 exhibited broad 
antiproliferative activity in 24 tumor cell lines of different 
tissue origin (half-maximal effective concentration [EC50], 
<14 nM) [22, 23]. Within 1 h of treatment, pHH3 was 
reduced, indicating Aurora B kinase inhibition. Polyploidy 
was observed in up to 80 % of cells 48 h following treat-
ment, with a subset of cells subsequently becoming senes-
cent and going through apoptosis [22, 23]. In studies utiliz-
ing in vivo xenograft models of human non-small cell lung 
cancer, colon carcinoma, and pancreas carcinoma, inhibi-
tion of Aurora B kinase with BI 811283 resulted in a dose-
dependent inhibition of tumor growth, and tumor regres-
sion was observed in some cases. A decrease in pHH3 was 
also observed, acting as a marker of Aurora B kinase inhi-
bition [24].
Here we report the findings of a phase I, dose-escala-
tion trial of BI 811283 that was performed in patients with 
advanced solid tumors. Two dosing schedules were exam-
ined, with the maximum tolerated dose (MTD) determined 
for each. The safety, pharmacokinetics, pharmacodynam-
ics, and antitumor activity of BI 811283 are also described.
Methods
Patient selection
Eligible patients were aged 18 years or older present-
ing with advanced, non-resectable and/or metastatic 
solid malignant tumors, who were either not amenable to 
established forms of treatment or for whom no therapy of 
proven efficacy was available, and with a life expectancy of 
≥6 months. Further eligibility criteria included an Eastern 
Cooperative Oncology Group performance status (ECOG 
PS) of ≤2; recovery from reversible toxicities of previous 
anticancer therapies; evaluable tumor deposits; secure cen-
tral venous access; adequate bone marrow, liver, and renal 
function [absolute neutrophil count ≥1500/mm3, platelet 
count ≥100 000/mm3, bilirubin ≤1.5 mg/dL (≤26 μmol/L, 
SI unit equivalent), aspartate amino transferase and/or 
alanine amino transferase ≤2.5 × upper limit of normal 
(ULN; if related to liver metastases then ≤5 × ULN), 
and serum creatinine ≤1.5 mg/dL (≤132 μmol/L, SI unit 
equivalent)]; no chemo-, radio-, immuno-, hormone-, or 
investigational therapy within 2 weeks prior to the start of 
treatment with the trial drug; no known brain metastases or 
second malignancy requiring therapy, and no serious illness 
or concomitant disease which could compromise patient 
safety (including clinically significant cardiovascular dis-
ease, left ventricular ejection fraction <50 %, myocardial 
infarction within the last 6 months prior to inclusion and/
or symptomatic coronary artery disease). Written informed 
consent was obtained from all study participants.
Study design and dose escalation
This was an open-label, first-in-human, phase I, dose-
escalation trial of BI 811283 in patients with advanced 
solid tumors, conducted at two sites in Germany (EudraCT 
No: 2007-000191-17, ClinicalTrials.gov Identifier: 
NCT00701324). The primary endpoint was determination 
of the MTD of BI 811283 administered as a 24-h continu-
ous infusion in a 4- or 3-week schedule. Several secondary 
endpoints were examined concurrently: the incidence and 
intensity of adverse events [AEs; determined by the com-
mon terminology criteria for AEs (Common Terminology 
Criteria for Adverse Events (CTCAE) version 3.0)], inci-
dence of dose-limiting toxicity (DLT), objective response 
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rate [according to the Response Evaluation in Solid 
Tumor (RECIST) criteria version 1.0] [25] and duration of 
response, pharmacodynamic analysis of skin biopsies for 
signs of target inhibition, and pharmacokinetic profile.
A modified 3 + 3 dose-escalation study design was 
chosen to evaluate the MTD of BI 811283, which was 
administered over 24 h by intravenous infusion (via central 
venous access). BI 811283 was administered on Days 1 and 
15 of a 4-week cycle (schedule A) or Day 1 of a 3-week 
cycle (schedule B). Good laboratory practice-toxicology 
studies provided the safety data in selecting an intrave-
nous 24 h continuous infusion (c.i.) and the two schedules 
tested, based on findings that the overall time of the plasma 
level over threshold was an important parameter for effi-
cacy and was superior when compared with a bolus regi-
men in an HCT 116 colorectal cancer model (Boehringer 
Ingelheim; data on file); in detail, weekly and 2-weekly 
administrations of BI 811283 as 24-h continuous infusion 
resulted in similarly strong antitumor activity in preclinical 
models. Thus, this provides the rationale for the two dos-
ing schedules tested in this trial. Cohorts of three patients 
were enrolled sequentially into escalating dose tiers of BI 
811283. The MTD was defined as the highest dose of BI 
811283 in which ≤1 of six patients experienced a DLT dur-
ing the first cycle of treatment. The starting dose level for 
schedule A was 5 mg estimated according to the Food and 
Drug Administration (FDA) flow diagram “General guide 
for starting dose selection for a cytotoxic agent in cancer 
patients”, with dose escalation in steps of 100 % until the 
first drug-related AE grade ≥2. Thereafter, escalation steps 
of BI 811283 were limited to ≤50 %. After the first DLT, 
escalation steps of no more than 35 % of the previous dose 
were made. To reduce the overall number of patients in 
the study, initial patient cohorts were assigned only to the 
4-week treatment cycle (schedule A), until the first occur-
rence in Cycle 1 of a drug-related AE grade ≥2. Thereafter, 
subsequent patients were randomized between the 4-week 
cycle (schedule A) and the 3-week cycle (schedule B) to 
determine the respective MTD in parallel groups. The start-
ing dose level in schedule B was the dose at which a first 
drug-related grade ≥2 AE occurred in schedule A. After 
determination of the MTD, up to 9 additional patients 
were entered at this dose level to obtain further safety data. 
Patients were treated until disease progression. However, if 
a patient who experienced disease progression tolerated the 
drug well and wished to continue with treatment, an intra-
patient dose escalation was allowed. Treatment was also 
terminated if a patient had an intolerable AE or withdrew 
consent, or if a treatment cycle was delayed for >2 weeks. 
The trial was conducted in accordance with the principles 
laid down by the Declaration of Helsinki and approved by 
the Independent Ethics Committees and/or Institutional 
Review Boards of the participating centers.
Definition of dose‑limiting toxicity
A DLT was recorded if one or more of the following events 
occurred during the first treatment cycle: (1) drug-related 
grade ≥3 non-hematological toxicity (except untreated 
nausea, vomiting, or diarrhea), (2) drug-related grade 4 
neutropenia for ≥7 days or febrile neutropenia, or (3) drug-
related grade 4 thrombocytopenia or anemia. Addition-
ally, for schedule A only, the following events on Day 15, 
if drug related, also constituted a DLT: (1) grade ≥2 non-
hematological toxicity (excluding alopecia and untreated 
nausea, vomiting, or diarrhea), or (2) grade ≥3 neutrope-
nia, thrombopenia, or anemia. The MTD was defined on 
the basis of DLT observed during the first treatment cycle 
only. However, DLTs observed after that time period were 
considered along with the type, number, and intensity of 
AEs to indicate how well BI 811283 was tolerated.
Study assessments
Safety
All treated patients were included in the safety evaluation. 
Key safety measures included evaluation of the incidence 
and intensity of AEs using the Medication Dictionary for 
Regulatory Activities (MedDRA) and classified according 
to CTCAE version 3.0, assessment of vital signs and labo-
ratory parameters, and 12-lead electrocardiogram (ECG) 
and echocardiography measurements.
Pharmacokinetics
Blood samples for the evaluation of pharmacokinetic 
parameters were collected 5 min before drug administra-
tion, at 1, 2, 4, 10, and 20 h during the infusion, at 23:59 
(just before the end of infusion), and at the following time-
points after the start of infusion: 24:15, 24:30, 25:00, 26:00, 
28:00 and 32:00 h (Day 2), 48:00 h (Day 3), 72:00 h (Day 
4), and 120 h (Day 6). Further samples were obtained in 
each subsequent treatment cycle (up to Cycle 6) just prior 
to the start and at the end of the infusion. Urine samples 
were also obtained after the first and second infusions of BI 
811283 (schedule A: Cycle 1 Days 1 and 15; schedule B: 
Cycle 1 Days 1 and 22). The concentration of BI 811283 
in plasma and urine was determined by a validated high-
performance liquid chromatography–tandem mass spec-
trometry (HPLC–MSMS) assay. Briefly, samples were 
subjected to protein precipitation with methanol. Then, the 
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samples were analyzed on a PerkinElmer Sciex API 5500 
LC-MSMS system using a Zorbax® Eclipse Plus C18 col-
umn. An electrospray ion source [atmospheric pressure 
ionization (API)] was used for ionization. Measurements 
were performed in the positive ionization mode. Preclinical 
assessments demonstrated that BI 811283 protein binding 
is dependent on the plasma concentrations of alpha-1-acid 
glycoprotein (AGP) (Boehringer Ingelheim, data on file). 
Therefore, AGP concentrations were determined in clini-
cal plasma samples following BI 811283 dosing and were 
obtained during the first two treatment cycles at the same 
time points as those collected for pharmacokinetic analy-
sis, with AGP concentration determined using a validated 
immunoturbidimetric assay. In the assay, AGP was precipi-
tated using a specific antiserum and the resulting turbidi-
metric reading at 340 nm was used to determine its concen-
tration. Pharmacokinetic analyses were summarized using 
descriptive statistics.
Pharmacodynamics
Target inhibition following BI 811283 dosing was assessed. 
Skin biopsies were analyzed for a reduction of pHH3, 
a marker of Aurora B kinase inhibition [26]. Three- to 
four-millimeter punch skin biopsies were obtained dur-
ing screening and within 6 h after the end of infusion on 
Day 16 of schedule A or Day 2 of schedule B of the first 
treatment cycle. The skin biopsies were divided, with one 
half each for western blotting and immunohistochemistry 
(IHC). For western blotting, the sample was lysed in Lys-
ing Matrix A (MP Biomedicals #6910-050) and lysis buffer 
[100 mM NaHCO3 pH 9.6, 1 mM dithiothreitol, Protease 
inhibitor cocktail (Serva 3910)]. Equivalent amounts of 
proteins from the cell lysates were applied to 12 % TRIS–
glycine gels (Invitrogen NuPAGE Novex NP0341BOX) and 
blotted with phospho-H3 antibody (Cell Signalling #9701) 
and H3 antibody (Cell Signalling #9715) to determine the 
ratio of phospho-H3/total H3 protein. For IHC analysis, 
the sample was fixed in formalin, embedded into paraffin 
with 5-µm sections prepared. The slides were probed with 
phospho-H3 antibody (Cell Signalling #9701) and coun-
terstained with Mayer’s hemalum (Merck 1.09249.1000). 
Epidermal areas were marked and measured, and positive 
nuclei counted with the aid of the NIKON image software. 
Quantification was done in a blinded fashion by two inde-
pendent researchers.
Serum levels of caspase-cleaved cytokeratin-18 (CK-
18) act as a marker of the cell apoptosis anticipated with 
Aurora B kinase inhibition by BI 811283 [27]. Therefore, 
plasma samples for quantifying the caspase-cleaved frag-
ment of CK-18 were obtained pre-dose and 48, 72, and 
120 h after the first two BI 811283 administrations in each 
schedule. Samples were also collected pre-dosing and 
120 h post-dosing, up to Cycle 6. Plasma concentrations of 
caspase-cleaved CK-18 were determined using a validated 
ELISA.
Antitumor activity
Objective tumor response was evaluated using computed 
tomography (CT) or magnetic resonance imaging (MRI) 
scans at baseline and at the end of every other treatment 
cycle, according to RECIST criteria version 1.0 [25].
Results
Patient demographics and disposition
A total of 129 patients were enrolled into the study which 
was performed between July 2007 and August 2011. Of 
these, 124 patients were entered to one of the two treat-
ment schedules and 121 were treated with study medica-
tion (schedule A: 63 patients; schedule B: 58 patients). 
Patient demographics and disease characteristics are sum-
marized in Table 1. Median patient age was 58 years (range 
23–79 years), and 47.1 % of patients were male. The major-
ity of patients (77.7 %) presented with stage IV disease at 
screening, with colorectal cancer being the most frequent 
tumor type (24.8 %). Most patients had undergone previous 
surgery (90.9 %) or systemic chemotherapy (92.6 %), and 
many were heavily pre-treated: 57 (47.1 %) had received 
≥4 lines of chemotherapy (Table 1).
Dose‑limiting toxicities, safety, and tolerability
Patients in the schedule A cohort were treated with BI 
811283 at doses from 5 to 140 mg. First-cycle DLTs were 
primarily hematological events; one patient treated with 
10 mg had raised liver function tests (Table 2). DLTs were 
seen in two of three patients treated with the 140 mg dose. 
The MTD was determined to be 125 mg; one patient in 
the initial cohort at this dose experienced grade 4 neutro-
penia on Day 15. Patients in the schedule B cohort were 
treated with BI 811283 starting at 13.5 mg and escalat-
ing to 300 mg. As with schedule A, DLTs were primarily 
hematological events; in addition, one patient treated with 
105 mg experienced grade 3 fatigue (Table 2). Two out of 
five patients experienced a DLT at the 270 mg dose. The 
MTD was determined to be 230 mg. During the data review 
meeting following the end of the study, five events of grade 
4 neutropenia in schedule B were retrospectively identified 
as possible DLTs (105 mg, n = 2; 125 mg, n = 1; 180 mg, 
n = 1; 230 mg, n = 1). In all five patients, the initial hema-
tology laboratory tests performed during Cycle 1 showed 
grade 4 neutropenia. However, there were no laboratory 
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tests performed on Day 7 or 8 after the start of the grade 
4 neutropenia to show whether neutropenia was still pre-
sent to qualify as a DLT (i.e., ≥7 days), although in all of 
these cases the neutropenia had resolved by Day 8–10 after 
the start of the grade 4 event. Five additional DLTs [grade 
4 febrile neutropenia (n = 2), grade 3 febrile neutropenia 
(n = 2), and grade 4 neutropenia ≥7 days (n = 1)] were 
also identified in the 230-mg dose expansion cohort of 
seven patients. Therefore, although per protocol the MTD 
was determined as 230 mg for schedule B, based on ret-
rospective DLTs from Cycle 1 and in patients enrolled in 
the expansion cohort, a lower dose may have been recom-
mended for further study. Expansion cohorts included nine 
additional patients in schedule A, and seven additional 
patients in schedule B treated at the respective MTDs (125 
and 230 mg). All patients in both treatment schedules had at 
least one AE during the treatment course, with 100 (82.6 %) 
patients having AEs that were considered drug related by 
the investigators [schedule A: n = 49 (77.8 %); schedule 
B: n = 51 (87.9 %)]. Drug-related AEs that occurred in 
≥10 % of all patients across all treatment cycles were neu-
tropenia (n = 40, 33.1 %), fatigue (n = 38, 31.4 %), leuko-
penia (n = 35, 28.9 %), nausea (n = 29, 24.0 %), alopecia 
(n = 24, 19.8 %), diarrhea (n = 20, 16.5 %), and decreased 
appetite (n = 18, 14.9 %). Tables 3 and 4 summarize the 
most common drug-related AEs in schedules A and B by 
dose. Serious AEs (SAEs) were reported in 61 (50.4 %) 
patients [schedule A: n = 33 (52.4 %); schedule B: n = 28 
(48.3 %)]. Thirteen of these patients had SAEs regarded 
as drug related [schedule A: n = 3 (4.8 %); schedule B: 
n = 10 (17.2 %)]. The most common drug-related SAE 
was febrile neutropenia (experienced by seven patients); 
Table 1  Patient demographics 
and disease characteristics
ECOG PS Eastern Cooperative Oncology Group performance status
a Schedule A: Days 1 and 15 of a 4-week cycle; schedule B: Day 1 of a 3-week cycle
b Includes head and neck (n = 3), esophagus (n = 3), stomach (n = 2), cervix/vagina/vulva (n = 3), gas-
trointestinal tract (n = 3), other endocrine cancer (n = 2), pleura (n = 2), lymphoma/leukemia (n = 1), 
small intestine (n = 1), lung (n = 1), anal region (n = 1), bladder (n = 1), urethra/penis (n = 1), small cell 
carcinoma (n = 1), mediastinum (n = 1), uterus (n = 1), adrenal (n = 1), and unknown (n = 3)
Schedule Aa (n = 63) Schedule Ba (n = 58) Total (N = 121)
Median age, y (range) 60 (23–76) 53 (32–79) 58 (23–79)
Gender, n (%)
 Male 29 (46.0) 28 (48.3) 57 (47.1)
 Female 34 (54.0) 30 (51.7) 64 (52.9)
Baseline ECOG PS, n (%)
 0 28 (44.4) 24 (41.4) 52 (43.0)
 1 32 (50.8) 32 (55.2) 64 (52.9)
 2 3 (4.8) 2 (3.4) 5 (4.1)
Type of cancer, n (%)
 Colorectal 7 (11.1) 23 (39.7) 30 (24.8)
 Skin 6 (9.5) 10 (17.2) 16 (13.2)
 Pancreas 6 (9.5) 5 (8.6) 11 (9.1)
 Sarcoma 6 (9.5) 2 (3.4) 8 (6.6)
 Breast 3 (4.8) 2 (3.4) 5 (4.1)
 Prostate 4 (6.3) 0 (0) 4 (3.3)
 Thyroid/parathyroid 4 (6.3) 0 (0) 4 (3.3)
 Non-small cell carcinoma 3 (4.8) 1 (1.7) 4 (3.3)
 Liver and biliary tree 2 (3.2) 2 (3.4) 4 (3.3)
 Ovary and fallopian tube 2 (3.2) 2 (3.4) 4 (3.3)
 Otherb 20 (31.7) 11 (19.0) 31 (25.6)b
Prior anticancer therapy, n (%)
 Chemotherapy 58 (92.1) 54 (93.1) 112 (92.6)
  1–3 31 (49.2) 24 (41.4) 55 (45.5)
  4–6 19 (30.2) 22 (37.9) 41 (33.9)
  >7 8 (12.7) 8 (13.8) 16 (13.2)
 Surgery 55 (87.3) 55 (94.8) 110 (90.9)
 Radiotherapy 35 (55.6) 24 (41.4) 59 (48.8)
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Table 2  DLTs observed during the first cycle in both treatment schedules
ALT alanine aminotransferase, AST aspartate aminotransferase, DLT dose-limiting toxicity, MTD maximum tolerated dose
a Defined as the maximum tolerated dose
b Seven patients initially plus nine patients in the expansion cohort
c Upon data review at the end of the study, two events in the schedule B 105 mg cohort (grade 4 neutropenia ≥7 days, n = 2) and one event 
(grade 4 neutropenia ≥7 days) in each of the following schedule B cohorts: 125, 180, and 230 mg were retrospectively determined to be DLTs, 
although they were not considered to be DLTs during MTD determination. These events were considered to have potentially met the study pro-
tocol definition for a DLT, but there was not sufficient information to conclusively determine their exact duration (i.e., no laboratory tests were 
performed on Day 7 or 8 after the start of the grade 4 neutropenia). The investigators and sponsor used a worst case/conservative approach and 
assumed that these were DLTs
Schedule A
BI 811283 dose (mg) n Patients with DLT DLT (n)
5 3 0 –
10 7 1 Grade 3 AST increased and grade 3 ALT increased (1)
13.5 3 0 –
18 3 0 –
24 4 0 –
32 3 0 –
43 5 0 –
58 3 0 –
78 7 1 Grade 3 neutropenia and grade 3 thrombocytopenia (1)
105 6 1 Grade 3 hemoglobin decreased (1)
125a 16b 1 Grade 4 neutropenia (1)
140 3 2 Grade 3 neutropenia (1); grade 4 neutropenia (1)
Schedule B
BI 811283 dose (mg) n Patients with DLT DLT (n) Patients with retrospectively 
identified potential DLT
DLT (n)
13.5 3 0 – – –
18 3 0 – – –
24 3 0 – – –
32 4 0 – – –
43 3 0 – – –
58 3 0 – – –
78 3 0 – – –
105 6 1c Grade 3 fatigue (1) 2 Grade 4 neutropenia ≥7 days 
(2);
125 3 0c – 1 Grade 4 neutropenia ≥7 days 
and grade 4 leukopenia (1)
150 3 0 – – –
180 3 0c – 1 Grade 4 neutropenia ≥7 days 
(1)
230 3 0c – 1 Grade 4 neutropenia ≥7 days 
(1)
300 3 2 Grade 4 febrile neutropenia 
(1); grade 3 febrile neutro-
penia (1)
– –
230 3 0 – – –





7 5 Grade 4 neutropenia ≥7 days 
(1); grade 4 febrile neutro-
penia (2); grade 3 febrile 
neutropenia (2)
– –
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other such events reported in more than one patient were 
leukopenia, neutropenia, vomiting, and diarrhea. A total 
of 22 (18.2 %) patients had fatal AEs [schedule A: n = 10 
(15.9 %); schedule B: n = 12 (20.7 %)]. None of the deaths 
were considered related to the study treatment. Overall, 
19 (15.7 %) patients had AEs that resulted in study drug 
discontinuation or a dose reduction [schedule A: n = 9 
(14.3 %); schedule B: n = 10 (17.2 %); Supplementary 
Table 1]. In 10 patients (five patients in each dosing sched-
ule), the AEs resulting in discontinuation or dose reduction 
were classified as significant according to the International 
Conference on Harmonization (ICH) E3.
Pharmacokinetics
Plasma concentrations of BI 811283 rose rapidly for sev-
eral hours after the start of the 24-h infusion, reaching 
maximum concentrations after 20–24 h (Fig. 1). This was 
followed by a biphasic decline in plasma BI 811283, which 
was initially very rapid such that most of the compound 
was eliminated within the first 6 h following the end of the 
infusion. The mean terminal half-life of BI 811283 was 
11.4–30.5 h for schedule A and 10.1–27.0 h for schedule 
B. In general, pharmacokinetic parameters were compara-
ble between the two schedules and there were no signifi-
cant differences between the first and second doses given 
to patients, regardless of treatment schedule. Although 
there was high inter-subject variability for both treatment 
schedules, the maximum measured concentration in plasma 
(Cmax) and the area under the concentration–time curve over 
the time interval from 0 extrapolated to infinity (AUC0–∞) 
values increased in a dose-dependent manner. The fraction 
of BI 811283 excreted in urine was low (ranging from 4 to 
12 % of the administered dose) and did not differ between 
the two treatment arms. AGP plasma concentrations did not 
change significantly with time after BI 811283 dosing and 
were not dependent on BI 811283 concentrations. There 
was a trend toward increased exposure to total BI 811283 
(bound and unbound) in patients with higher AGP plasma 
concentrations, although there was high variability.
Pharmacodynamics
In total, 28 out of 63 patients in schedule A [5, 10, 18, 24, 
43, 125, and 140 mg (n = 2 each); 58 mg (n = 3); 78 mg 
(n = 4); 105 mg (n = 5)], and 28 out of 58 patients in 
schedule B [32 and 300 mg (n = 1 each); 13.5, 18, 43, 58, 
105, 125 (n = 2 each); 150 mg (n = 3); 270 mg (n = 4); 
230 mg (n = 7)] provided skin biopsies for pharmacody-
namic analyses. Two different types of analyses were per-
formed: an IHC determination of cells with nuclei that were 
positive for pHH3 and a western blot analysis to determine 
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analyses resulted in a low to undetectable pHH3 band, 
sometimes in combination with a very dominant globin 
band, which interfered with the pHH3 signal. IHC analyses 
using formalin-fixed paraffin-embedded sections revealed 
a trend for a reduction in the number of phospho-histone 
H3-positive nuclei in the epidermis with increasing doses 
of BI 811283 from 58 mg upward in schedule A, and from 
43 mg upward in schedule B [Fig. 2 and example images 
from a patient receiving schedule A treatment (Supplemen-
tary Fig 1)], suggesting Aurora B kinase inhibition in this 
patient population [11, 28]. There was no consistent trend 
regarding the level of caspase-cleaved CK-18 in plasma 
after infusion of BI 811283, no consistency between the 
first and second infusions, and data obtained from the effect 
curves were extremely variable (Supplementary Fig 2 and 
3).
Antitumor activity
No patients in either treatment schedule achieved an objec-
tive response. However, 19 (30 %) patients in schedule A 
and 19 (33 %) patients in schedule B achieved clinical ben-
efit from treatment [defined as stable disease (SD; n = 37) 
or non-evaluable but clinically not progressive disease 
(n = 1)]. To confirm a status of SD, an overall response 
assessment that met the SD criteria was to be recorded 
at least 42 days after study entry. Ten patients with SD 
received ≥10 cycles of treatment [tumor types: melanoma 
(n = 3), thyroid or parathyroid (n = 2), sarcoma (n = 2), 
breast (n = 1), lung (n = 1), and colorectal cancer (n = 1)].
Discussion
Novel treatment strategies for patients with advanced solid 
tumors are urgently needed. Although antimitotic drugs in 
the form of microtubule-targeting agents (MTAs), such as 
the taxanes, are one of the most widely used classes of can-
cer therapeutics, the broad and often toxic effects of these 
agents, together with the emergence of MTA resistance, 
have triggered interest in new strategies that involve selec-
tive inhibition of enzymes involved in the regulation of 
mitosis [29, 30]. Aurora B kinase is one such enzyme that 
plays several important roles in mitosis [2, 31, 32]. This 
fact, coupled with its elevated expression across a wide 
range of tumor types suggests that this enzyme could be an 
effective therapeutic target in oncology [33].
This phase I clinical trial was designed as an open, par-
allel group, first-in-human study to define the MTD of BI 
811283, an inhibitor of Aurora B kinase, in patients with 
advanced solid tumors. The MTD of BI 811283 was deter-
mined as 125 mg on Days 1 and 15 of a 4-week cycle 




























































































































































































































































































































































































































































































































413Cancer Chemother Pharmacol (2016) 78:405–417 
1 3
Fig. 1  Geometric mean plasma concentrations of BI 811283 following 24-h intravenous infusion in schedule A (a) and schedule B (b) (linear 
scale)
Fig. 2  Effect of BI 811283 following 24-h intravenous infusion on histone H3 phosphorylation measured by immunohistochemistry in schedule 
A (a) and schedule B (b)
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(schedule B). The most common DLTs observed in both 
schedules were primarily hematological events, particularly 
neutropenia. One patient with metastatic soft tissue sar-
coma and no liver metastases treated with 10 mg BI 811283 
in schedule A experienced a DLT of grade 3 liver enzyme 
(alanine and aspartate aminotransferase) elevation in Cycle 
1 which resolved spontaneously within 5 days. She again 
developed grade 3/4 liver enzyme elevation following treat-
ment on Cycle 2 Day 15 which did not improve sufficiently 
for her to receive subsequent treatment, and she discontin-
ued from the study. Given the recurrence of this AE upon 
rechallenge of the drug, it was deemed almost certainly 
drug related. This was the only occurrence of dose-limit-
ing liver enzyme elevation in the study. Such DLTs do not 
appear to be typical of this class of compound, although 
DLTs of liver enzyme elevations were observed with the 
Aurora A kinase inhibitor MLN8054, and development of 
this compound was ceased in favor of alisertib (MLN8237) 
[34]. The retrospective identification of additional AEs in 
schedule B which possibly fulfilled the criteria for DLTs 
and the additional DLTs identified in the expansion cohort 
of 230 mg in schedule B suggests that the MTD and rec-
ommended phase II dose for further study may have been 
less than 230 mg with schedule B. However, due to the lack 
of promising efficacy data in this study and the develop-
ment of an oral Aurora kinase inhibitor [35–37] offering 
improved convenience to the patient compared with BI 
811283 (which requires 24-h continuous infusion through 
a central line), the clinical development of BI 811283 was 
halted.
No patients achieved an objective response with BI 
811283 in this study. The best overall response was SD in 
both treatment schedules, observed in approximately 30 % 
of patients, all of whom had previously been heavily pre-
treated. This is not unexpected; however, as this outcome 
is consistent with the cytostatic mechanism of action of 
this class of drugs and comparable with the efficacy data 
observed in phase I trials of other Aurora kinase inhibitors 
[35, 36, 38–41].
The overall safety profile was as to be expected in a pop-
ulation of patients with advanced cancer. In addition to the 
AEs typically associated with the underlying disease, the 
most common toxicities were hematological. BI 811283 is 
known to cause a transient inhibition of the proliferation 
of normal dividing cells in the bone marrow, resulting in a 
temporary decrease of blood cells and platelets. Inhibition 
of mucosal proliferation can also occur with BI 811283, 
leading to gastrointestinal symptoms such as nausea, diar-
rhea, and abdominal pain. These AEs are not considered 
unusual following treatment with a compound targeting 
rapidly dividing cells, and similar toxicities were observed 
in phase I trials of other Aurora kinase inhibitors [35, 36, 
41].
Pharmacokinetic analyses showed that plasma concen-
trations of BI 811283 rose rapidly in patients during the 
first few hours of the 24-h infusion, with maximum con-
centrations generally reached 20–24 h after the start of the 
infusion. This was followed by a rapid, biphasic decline. 
Pharmacokinetic parameters did not differ between the two 
treatment arms and there were no meaningful differences 
in pharmacokinetic parameters of BI 811283 between the 
first and second doses given to patients, regardless of treat-
ment schedule. The fraction of BI 811283 excreted in urine 
was low and did not differ between the two treatment arms. 
Although there was high variability, exposure of total BI 
811283 appeared to increase in patients with higher AGP 
concentrations. However, unbound BI 811283 was not 
determined in this study, so the relationship to AGP expo-
sure in this case is not known.
During mitosis, histone H3 is phosphorylated by Aurora 
kinase B on serine 10 [11, 28]. Aberrant pHH3 is associ-
ated with chromosome instability and carcinogenesis [11, 
26]. A reduction in phosphorylation on serine 10 indicates 
Aurora kinase B inhibition. Indeed in preclinical studies, 
BI 811283 reduced histone H3 phosphorylation in mul-
tiple cancer cell lines [22, 24]. In this exploratory study, 
pHH3 was measured using both western blotting and IHC. 
Results from the western blot analyses were not considered 
meaningful due to a low to undetectable pHH3 band, some-
times in combination with a very dominant globin band, 
which interfered with the pHH3 signal. In contrast, IHC, 
which relies on single cell analysis, had a signal that was 
highly concentrated in the rare mitotic cells resulting in 
a signal-to-noise ratio that was much improved. The IHC 
analyses revealed a trend for a reduction in the ratio of cel-
lular pHH3 to total histone H3 with increasing doses of BI 
811283 in the skin as surrogate tissue, suggesting a dose-
dependent inhibition of Aurora B kinase in this patient pop-
ulation. Among the 10 patients who achieved SD for ≥10 
cycles, skin biopsy samples from only four patients were 
evaluable (two patients from each treatment arm). Of these 
four patients, the biopsy samples from only two patients 
showed a pharmacodynamics effect; therefore, it is diffi-
cult to conclude whether the pharmacodynamics effect had 
any correlation with clinical outcome. Overall, these results 
were not unexpected, due to differences in molecular and 
physiological characteristics between tumor versus skin tis-
sue, and these analyses provide encouraging clinical data 
regarding BI 811283 target engagement. There was no con-
sistent increase seen in caspase-cleaved CK-18, a marker of 
tumor cell death [27] in plasma samples of patients treated 
with BI 811283. Therefore, caspase-cleaved CK-18 was 
not an informative clinical biomarker of Aurora B kinase 
inhibition by BI 811283 in this study.
There are several Aurora kinase inhibitors currently 
in clinical development, which either specifically target 
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Aurora A or Aurora B kinase, or demonstrate some activ-
ity toward both kinases [42]. Preliminary evidence from a 
phase II study indicates that alisertib (MLN8237), an oral 
Aurora A kinase inhibitor, has a generally manageable 
safety profile and results in durable disease control in mul-
tiple cancer types [37]. The Aurora A kinase inhibitor danu-
sertib has shown an acceptable safety profile and promising 
clinical activity in patients with advanced hematological 
malignancies [43], but limited activity in phase I/II stud-
ies in advanced solid tumors [44, 45]. The most widely 
tested Aurora B kinase inhibitor is barasertib (AZD1152), 
which has been evaluated in both patients with advanced 
solid tumors and those with hematological cancers. While 
barasertib demonstrated limited activity in solid tumors 
[38, 46], greater activity has been observed in patients with 
acute myeloid leukemia (AML) [47–50]. In these patients, 
barasertib has demonstrated clinical activity in several 
phase I/II trials as monotherapy (hematological response 
rate of 19–25 %) and in combination with low-dose cyto-
sine arabinoside (LDAC; response rate of 45 %). Grade 
≥3 neutropenia/febrile neutropenia was reported as a com-
mon AE in these studies. Barasertib was also compared to 
LDAC in a randomized phase II trial in elderly patients 
with AML, demonstrating higher complete response rates 
(35.4 vs 11.5 %); however, barasertib was much less toler-
able than LDAC in these patients (71 vs 15 % stomatitis; 67 
vs 19 % febrile neutropenia) [47]. Another Aurora B kinase 
inhibitor, BI 831266, has also been recently studied in a 
phase I trial of patients with advanced solid tumors. Simi-
lar to the agent investigated in the current study, BI 831266 
treatment resulted in objective response in only one patient 
(cervical cancer), with 16 % of patients experiencing SD 
[39]. The BI 831266 trial was discontinued based on these 
data, as well as the limited activity displayed by BI 811283 
in this population.
Although all Aurora kinases are involved in cell division, 
only Aurora A regulates centrosome maturation/separation 
and bipolar spindle assembly, whereas Aurora B and C are 
involved in the regulation of mitotic chromosome dynam-
ics [43]. Based on these different intracellular functions, it 
has been hypothesized that inhibition of multiple Aurora 
kinases may provide better antitumor activity. Agents that 
target both Aurora A and B kinases are currently in early-
stage clinical development (e.g., PF-03814735, AT9283) in 
both solid tumors and hematological malignancies; how-
ever, these agents have shown limited antitumor activity 
thus far in phase I trials [40, 43].
Conclusions
In summary, this phase I trial demonstrated an acceptable 
safety profile with BI 811283 administered on two different 
treatment schedules. MTDs were determined as 125 mg 
(Days 1 and 15 of a 4-week cycle) and 230 mg (Day 1 of 
a 3-week cycle); however, the retrospective identification 
of additional potential AEs in schedule B during a data 
review at the end of the study suggests that the MTD may 
have been less than 230 mg. The limited antitumor activ-
ity observed with BI 811283 does not support its contin-
ued development in solid tumors. Further biomarker studies 
would be beneficial to better understand the role of Aurora 
kinase inhibition in tumor development and anticancer 
therapy.
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